Bionano reports third quarter 2024 results and highlights recent business progress

Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clinical service products. q3 2024 revenue represents a 35% decrease from q3 2023 total installed base of 368 optical genome mapping (ogm) systems as of q3 2024, which represents a 22% increase over q3 2023 sold 7,835 nanochannel array flowcells in q3 2024, which represents a 27% increase from the number of flowcells sold in q3 2023 conference call today, november 13, 2024 at 4:30 pm et san diego, nov. 13, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today reported financial results for the third quarter ended september 30, 2024.
BNGO Ratings Summary
BNGO Quant Ranking